Endologix gets US nod for AAA (abdominal aortic aneurysms) graft
This article was originally published in Clinica
The FDA has given Endologix conditional approval to join the US market for minimally invasive grafts for treating abdominal aortic aneurysms (AAA).
You may also be interested in...
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.